Nano-Microparticle Platforms in Developing Next-Generation Vaccines
Open Access
- 5 June 2021
- Vol. 9 (6), 606
- https://doi.org/10.3390/vaccines9060606
Abstract
The first vaccines ever made were based on live-attenuated or inactivated pathogens, either whole cells or fragments. Although these vaccines required the co-administration of antigens with adjuvants to induce a strong humoral response, they could only elicit a poor CD8+ T-cell response. In contrast, next-generation nano/microparticle-based vaccines offer several advantages over traditional ones because they can induce a more potent CD8+ T-cell response and, at the same time, are ideal carriers for proteins, adjuvants, and nucleic acids. The fact that these nanocarriers can be loaded with molecules able to modulate the immune response by inducing different effector functions and regulatory activities makes them ideal tools for inverse vaccination, whose goal is to shut down the immune response in autoimmune diseases. Poly (lactic-co-glycolic acid) (PLGA) and liposomes are biocompatible materials approved by the Food and Drug Administration (FDA) for clinical use and are, therefore, suitable for nanoparticle-based vaccines. Recently, another candidate platform for innovative vaccines based on extracellular vesicles (EVs) has been shown to efficiently co-deliver antigens and adjuvants. This review will discuss the potential use of PLGA-NPs, liposomes, and EVs as carriers of peptides, adjuvants, mRNA, and DNA for the development of next-generation vaccines against endemic and emerging viruses in light of the recent COVID-19 pandemic.Keywords
This publication has 132 references indexed in Scilit:
- Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine–loaded microspheres against dengue 2 virusInternational Journal of Nanomedicine, 2013
- Liposome: classification, preparation, and applicationsNanoscale Research Letters, 2013
- Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3Frontiers in Microbiology, 2013
- HIV Type 1 Gag as a Target for Antiviral TherapyAIDS Research and Human Retroviruses, 2012
- PLGA, PLGA-TMC and TMC-TPP Nanoparticles Differentially Modulate the Outcome of Nasal Vaccination by Inducing Tolerance or Enhancing Humoral ImmunityPLOS ONE, 2011
- Liposome-Coupled Antigens Are Internalized by Antigen-Presenting Cells via Pinocytosis and Cross-Presented to CD8+ T CellsPLOS ONE, 2010
- Development of a nanoparticulate formulation of retinoic acid that suppresses Th17 cells and upregulates regulatory T cellsSelf/Nonself, 2010
- Current advances in research and clinical applications of PLGA-based nanotechnologyExpert Review of Molecular Diagnostics, 2009
- Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene InsertsToxicological Sciences, 2006
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004